Companhia de saneamento Basico Do Estado De Sao Paulo Sabesp (SBS)
(Delayed Data from NYSE)
$17.75 USD
+0.06 (0.34%)
Updated Aug 12, 2024 04:00 PM ET
After-Market: $17.75 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SBS 17.75 +0.06(0.34%)
Will SBS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SBS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SBS
Here's Why Sabesp (SBS) is Poised for a Turnaround After Losing -11.66% in 4 Weeks
SBS or GWRS: Which Is the Better Value Stock Right Now?
SBS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should Value Investors Buy Companhia de saneamento Basico Do Estado De Sao Paulo Sabesp (SBS) Stock?
Here's What Could Help Sabesp (SBS) Maintain Its Recent Price Strength
Are Utilities Stocks Lagging E.ON (EONGY) This Year?
Other News for SBS
SBS Stock Earnings: Companhia De Saneamento Beats EPS, Beats Revenue for Q2 2024
Hauck & Aufhaeuser Sticks to Its Hold Rating for STRATEC Biomedical (0RAR)
Kepler Capital Reaffirms Their Hold Rating on STRATEC Biomedical (0RAR)
Berenberg Bank Remains a Hold on STRATEC Biomedical (0RAR)
Warburg Research Sticks to Their Hold Rating for STRATEC Biomedical (0RAR)